BioRestorative Therapies announces new data on BRTX-100 presented at ORS 2025

BioRestorative Therapies (BRTX) announced that its Vice President of Research and Development, Francisco Silva, presented 26-52 week blinded data from the first 15 patients with chronic lumbar disc disease, cLDD, enrolled in the ongoing Phase 2 clinical trial of BRTX-100 at the Orthopaedic Research Society, ORS, annual meeting, taking place February 7-11, 2025 in Phoenix, AZ. The safety and efficacy of BRTX-100 in treating cLDD is being evaluated in a Phase 2, prospective, randomized, double-blinded and controlled study. A total of up to 99 eligible subjects will be enrolled at up to 16 clinical sites in the United States. Subjects included in the trial will be randomized 2:1 to receive either BRTX-100 or placebo. No serious adverse events were reported, and there was no dose (40X106 cells) limiting toxicity at 26-52 weeks.